Fig. 7: TPX2 promotes the resistance of HCC cells to sorafenib in an intrahepatic subcutaneous tumor model. | Cell Death & Disease

Fig. 7: TPX2 promotes the resistance of HCC cells to sorafenib in an intrahepatic subcutaneous tumor model.

From: TPX2 enhances the transcription factor activation of PXR and enhances the resistance of hepatocellular carcinoma cells to antitumor drugs

Fig. 7: TPX2 promotes the resistance of HCC cells to sorafenib in an intrahepatic subcutaneous tumor model.

The HepG2 cells were transfected with control, TPX2 or siTPX2 and injected into the subcutaneous position of nude mice. The tumor tissues were prepared as the micro-blocks for constructing the intrahepatic HCC model. The mice received the 1.0 mg/kg concentration of sorafenib via oral administration. The results were shown as images of micro positron emission tomography (microPET) (A) or quantitative results. *P < 0.05.

Back to article page